EIF2AK2

Disease related genes, Enzymes, Human disease related genes, Metabolic proteins, Potential drug targets

Intracellular

Low cell type specificity

Low immune cell specificity

Low cell line specificity

Homodimer. Interacts with STRBP (By similarity). Interacts with DNAJC3. Forms a complex with FANCA, FANCC, FANCG and HSP70. Interacts with ADAR/ADAR1. Interacts with IRS1 (By similarity). The inactive form interacts with NCK1 and GSN. Interacts (via the kinase catalytic domain) with STAT3 (via SH2 domain), TRAF2 (C-terminus), TRAF5 (C-terminus) and TRAF6 (C-terminus). Interacts with MAP2K6, IKBKB/IKKB, NPM1, TARBP2, NLRP1, NLRP3, NLRC4 and AIM2. Interacts (via DRBM 1 domain) with DUS2L (via DRBM domain). Interacts with DHX9 (via N-terminus) and this interaction is dependent upon activation of the kinase. (Microbial infection) Interacts with human herpes simplex virus 1 (HHV-1) protein US11 in an RNA-dependent manner. (Microbial infection) The inactive form interacts with Toscana virus (TOS) NSS. (Microbial infection) Interacts with herpes virus 8 protein v-IRF2; this interaction inhibits EIF2AK2 activation. (Microbial infection) Interacts with vaccinia protein E3. (Microbial infection) Interacts (via N-terminus) with Hepatitis C virus (HCV) mature core protein (via N-terminus); this interaction induces the autophosphorylation of EIF2AK2. (Microbial infection) Interacts with Hepatitis C virus (HCV) non-structural protein 5A (NS5A); this interaction leads to disruption of EIF2AK2 dimerization by NS5A. (Microbial infection) Interacts with Hepatitis C virus (HCV) envelope glycoprotein E2; this interaction inhibits EIF2AK2 and blocks its inhibitory effect on protein synthesis and cell growth. (Microbial infection) Interacts with human respiratory syncytial virus (HRSV) nucleoprotein; this interaction inhibits EIF2AK2 phosphorylation of EIF2S1 and blocks EIF2AK2-mediated translation shutoff.

Kinase, RNA-binding, Serine/threonine-protein kinase, Transferase, Tyrosine-protein kinase